The yield of programmed ventricular stimulation in mitral valve prolapse patients with ventricular arrhythmias.
A high-risk subset of patients with mitral valve prolapse (MVP) and a predisposition to sudden cardiac death (SCD) has been proposed. We analyzed the results of programmed ventricular stimulation (PVS) in 20 patients with MVP and ventricular arrhythmias (ventricular premature depolarization in 6, ventricular couplets in 2, nonsustained ventricular tachycardia [VT] in 7, ventricular fibrillation [VF] in 5) and in 12 "normal" control subjects. With the use of an identical stimulation protocol from the right ventricular apex (twice diastolic threshold, three extrastimuli), 9 of 20 MVP patients and 1 of 12 normal subjects had inducible ventricular arrhythmias (p less than 0.05). When more aggressive attempts at ventricular stimulation were used, an additional five MVP patients had positive responses to PVS while no normal subjects did. In the MVP group, the following arrhythmias were induced: nonsustained polymorphic VT in 10, VF in three, and ventricular flutter in one. In all but two patients, triple ventricular extrastimuli were required to elicit this response. Two of the 10 MVP patients undergoing electropharmacologic testing had a successful antiarrhythmic regimen identified, while 13 patients were discharged on empiric antiarrhythmic therapy. At a follow-up of 19.8 +/- 13.1 months, all 19 MVP patients who could be contacted were alive. Five patients had symptomatic recurrences at follow-up including two SCD survivors (VT in one and VF in one). In conclusion, it was found that the majority of MVP patients with ventricular arrhythmias have inducible ventricular tachyarrhythmias during PVS and are more susceptible to this than patients without structural heart disease.(ABSTRACT TRUNCATED AT 250 WORDS)
D000328:Adult; D000638:Amiodarone / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000503:physiopathology*; D004562:Electrocardiography; D004594:Electrophysiology; D005260:Female; D006323:Heart Arrest / Q000209:etiology; D006352:Heart Ventricles / Q000503:physiopathology; D006801:Humans; D008297:Male; D008801:Mexiletine / Q000627:therapeutic use; D008875:Middle Aged; D008945:Mitral Valve Prolapse / Q000150:complications / Q000503:physiopathology*; D011342:Procainamide / Q000627:therapeutic use; D011405:Propafenone; D011427:Propiophenones / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D012306:Risk
D011427:Propiophenones; D008801:Mexiletine; D011405:Propafenone; D011433:Propranolol; D011342:Procainamide; D000638:Amiodarone